"Die Medizinische Klinik III betreut Patienten mit Erkrankungen aus allen Teilbereichen der internistischen Hämatologie und Onkologie. Dabei deckt die Klinik sowohl im Bereich der soliden Tumoren wie auch im Bereich der hämatologischen Erkrankungen ein breites Spektrum an Schwerpunkten ab, welches unter den universitären Kliniken für Hämatologie und Onkologie in Deutschland eine herausragende Stellung einnimmt."

During the past decade, Klinikum der Universität München, Campus Großhadern; Medizinische Klinik und Poliklinik III conducted 15 clinical trials. In the 10-year time frame, 15 clinical trials started and 5 clinical trials were completed, i.e. on average, 33.3% percent of trials that started reached the finish line to date. In the past 5 years, 8 clinical trials started and 3 clinical trials were completed. i.e. 37.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Klinikum der Universität München, Campus Großhadern; Medizinische Klinik und Poliklinik III" #1 sponsor was "Hoffmann-La Roche" with 6 trials, followed by "Celgene" with 3 trials sponsored, "Christian Buske" with 2 trials sponsored, "IFAG AG" with 2 trials sponsored and "Institut de Recherches Internationales Servier" with 2 trials sponsored. Other sponsors include 2 different institutions and companies that sponsored additional 12 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Klinikum der Universität München, Campus Großhadern; Medizinische Klinik und Poliklinik III" #1 collaborator was "ADIR, a Servier Group company" with 2 trials as a collaborator, "Hiscia Society for Cancer Research" with 2 trials as a collaborator, "University of Ulm" with 2 trials as a collaborator, "Zentrum für Klinische Studien Ulm" with 2 trials as a collaborator and "AbbVie" with 1 trials as a collaborator. Other collaborators include 12 different institutions and companies that were collaborators in the rest 22 trials.

According to Clinical.Site data, the most researched conditions in "Klinikum der Universität München, Campus Großhadern; Medizinische Klinik und Poliklinik III" are "Glioblastoma" (2 trials), "Lymphocytic Leukemia, Chronic" (2 trials), "Metastatic Colorectal Cancer" (2 trials), "Acute Myeloid Leukemia" (1 trials) and "Colorectal Cancer" (1 trials). Many other conditions were trialed in "Klinikum der Universität München, Campus Großhadern; Medizinische Klinik und Poliklinik III" in a lesser frequency.

Most popular intervention types in "Klinikum der Universität München, Campus Großhadern; Medizinische Klinik und Poliklinik III" are "Drug" (19 trials), "Biological" (1 trials), "Device" (1 trials), "Procedure" (1 trials) and "Radiation" (1 trials). Other intervention types were less common.

The name of intervention was led by "Bevacizumab" (4 trials), "Rituximab" (4 trials), "Atezolizumab" (2 trials), "Bendamustine" (2 trials) and "Durvalumab" (2 trials). Other intervention names were less common.

The vast majority of trials in "Klinikum der Universität München, Campus Großhadern; Medizinische Klinik und Poliklinik III" are 22 trials for "All" genders.

Currently, there are NaN active trials in "Klinikum der Universität München, Campus Großhadern; Medizinische Klinik und Poliklinik III". undefined are not yet recruiting, 5 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 8 completed trials in Klinikum der Universität München, Campus Großhadern; Medizinische Klinik und Poliklinik III, 1 suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Klinikum der Universität München, Campus Großhadern; Medizinische Klinik und Poliklinik III, 4 "Phase 1" clinical trials were conducted, 8 "Phase 2" clinical trials and 10 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".